Holen Sie sich die Stockscreener-App
6.66
3.42%
0.22
Schlusskurs vom Vortag:
$6.44
Offen:
$6.45
24-Stunden-Volumen:
271.91K
Relative Volume:
0.66
Marktkapitalisierung:
$441.96M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-11.10
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
+1.99%
1M Leistung:
-9.26%
6M Leistung:
-43.65%
1J Leistung:
-0.60%
1-Tages-Spanne:
$6.3341
$6.67
1-Wochen-Bereich:
$6.3341
$6.72
52-Wochen-Spanne:
$5.28
$14.38
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Vergleichen Sie BVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
6.66 | 433.32M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
133.71 | 231.29B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.10 | 157.07B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.01 | 146.67B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.54 | 104.07B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.72 | 44.71B | 5.54B | 4.18B | 623.10M | 7.00 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Cetera Investment Advisers Sells 1,805 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus’ Cut Losses 46%, Organic Sales Up 5% - Orthopedics This Week
Millennium Management LLC Sells 60,811 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Janus Henderson Group PLC Acquires Shares of 17,200 Bioventus Inc. (NYSE:BVS) - Defense World
Balyasny Asset Management L.P. Invests $133,000 in Bioventus Inc. (NYSE:BVS) - Defense World
BNP Paribas Financial Markets Invests $1.66 Million in Bioventus Inc. (NYSE:BVS) - Defense World
Price T Rowe Associates Inc. MD Has $160,000 Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
(BVS) On The My Stocks Page - news.stocktradersdaily.com
Bioventus reiterates 2025 guidance with focus on growth and profitability - MSN
Barclays PLC Has $696,000 Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus (BVS) Price Target Trimmed by Craig-Hallum Analyst | BVS Stock News - GuruFocus
Bioventus Inc. (NASDAQ:BVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Bioventus (NASDAQ:BVS) Using Too Much Debt? - simplywall.st
Bioventus First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures - Yahoo Finance
Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures By GuruFocus - Investing.com Canada
Bioventus Reports Q1 2025 Financial Performance - TipRanks
Bioventus: Q1 Earnings Snapshot - CTPost
Bioventus Earnings Call: Growth Amid Challenges - TipRanks
Financial Fitness Check: Examining Bioventus Inc (BVS)’s Key Ratios - DWinneX
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Bioventus Q1 2025 slides: 5% organic growth despite revenue decline, maintains guidance - Investing.com Canada
Earnings call transcript: Bioventus Q1 2025 beats EPS forecast but faces stock dip - Investing.com Nigeria
Bioventus Inc. Q1 Loss Narrows - Nasdaq
Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Bioventus (BVS) Exceeds Q1 Revenue Expectations with Strong Perf - GuruFocus
Bioventus Inc Q1 2025 Earnings: Revenue Hits $123.9M, Beating Es - GuruFocus
Bioventus (BVS) Exceeds Q1 Revenue Expectations with Strong Performance | BVS Stock News - GuruFocus
Bioventus reports Q1 revenue and earnings above estimates, shares dip By Investing.com - Investing.com Nigeria
Bioventus reports Q1 revenue and earnings above estimates, shares dip - Investing.com Australia
Bioventus Reports First Quarter Financial Results | BVS Stock Ne - GuruFocus
Bioventus Reports First Quarter Financial Results - The Manila Times
Bioventus Reports First Quarter Financial Results | BVS Stock News - GuruFocus
Bioventus Inc. Reports Q1 2025 Financial Results: Revenue Decline of 4.3% but Organic Growth of 5.0% and Improved Non-GAAP EPS - Nasdaq
Bioventus Inc. SEC 10-Q Report - TradingView
(BVS) Trading Report - news.stocktradersdaily.com
Examining the Future: Bioventus's Earnings Outlook - Nasdaq
Bioventus Inc (BVS) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
Bioventus Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Legal & General Group Plc Raises Position in Bioventus Inc. (NYSE:BVS) - Defense World
Orthobiologics Market Growth Statistics & Future Prospects | Medtronic, Orthofix Medical, Bioventus - openPR.com
Bioventus Q1 2025 Earnings Preview: Key Metrics and Business Updates Coming May 6 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
LPL Financial LLC Has $433,000 Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Alliancebernstein L.P. Sells 3,500 Shares of Bioventus Inc. (NYSE:BVS) - Defense World
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):